Minerva Neurosciences (NERV)

• Market cap: $14.8M
• 1 day: 0.00%
• 5 days: -7.02%
• 1 month: -6.19%
• 3 months: -21.48%
• 6 months: -34.77%
• Year to date: -65.53%
• 1 year: -67.53%
• 5 years: -96.32%
• 10 years: -95.29%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.

Employees: 9

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

0.3% more ownership

Funds ownership: 30.0% [Q2] → 30.3% (+0.3%) [Q3]

0% more funds holding

Funds holding: 21 [Q2] → 21 (+0) [Q3]

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

15% less capital invested

Capital invested by funds: $6.69M [Q2] → $5.65M (-$1.03M) [Q3]

20% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 5

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $5 136% upside
• Avg. target: $5 136% upside
• High target: $5 136% upside

1 analyst rating

• positive: 0 0%
• neutral: 1 100%
• negative: 0 0%

HC Wainwright & Co. Douglas Tsao 41% 1-year accuracy 68 / 167 met price target

136% upside $5

Neutral Reiterated

6 Nov 2024